nach oben

Erschienen in:

25.04.2023 | Main topic

Chronic thromboembolic pulmonary hypertension—medical, interventional, and surgical therapy

verfasst von: PD Dr. med. Christoph B. Wiedenroth, Diethard Pruefer, Miriam S. D. Adameit, Eckhard Mayer, Stefan Guth

Erschienen in: Herz | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is an important late sequela of pulmonary embolism and a common form of pulmonary hypertension. Currently, three specific treatment modalities are available: pulmonary endarterectomy, balloon pulmonary angioplasty, and targeted medical therapy. The treatment decision depends mainly on the exact localization of the underlying pulmonary arterial obstructions. Pulmonary endarterectomy is the gold standard treatment of CTEPH. For inoperable patients, riociguat and treprostinil are approved. In addition, interventional therapy is recommended if appropriate target lesions are proven. Evaluation and treatment of patients with CTEPH in experienced centers are mandatory.

Humbert M, Kovacs G, Hoeper MM et al (2022) 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 25:2200879. https://doi.org/10.1183/13993003.00879-2022CrossRef

Guerin L, Couturaud F, Parent F et al (2014) Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb Haemost 112:598–605. https://doi.org/10.1160/TH13-07-0538CrossRefPubMed

Pengo V, Lensing AWA, Prins MH et al (2004) Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350(22):2257–2264. https://doi.org/10.1056/NEJMoa032274CrossRefPubMed

Klok FA, van Kralingen KW, van Dijk APJ et al (2010) Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Haematologica 95(6):970–975. https://doi.org/10.3324/haematol.2009.018960CrossRefPubMedPubMedCentral

Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A et al (2017) Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur Respir J 49(2):1601792. https://doi.org/10.1183/13993003.01792-2016CrossRefPubMed

Bochenek ML, Rosinus NS, Lankeit M et al (2017) From thrombosis to fibrosis in chronic thromboembolic pulmonary hypertension. Thromb Haemost 117(4):769–783. https://doi.org/10.1160/TH16-10-0790CrossRefPubMed

Klok FA, Dzikowska-Diduch O, Kostrubiec M et al (2016) Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. J Thromb Haemost 14:121–128. https://doi.org/10.1111/jth.13175CrossRefPubMed

Lang IM, Pesavento R, Bonderman D, Yuan JX (2013) Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J 41(2):462–468. https://doi.org/10.1183/09031936.00049312CrossRefPubMed

Narechania S, Renapurkar R, Heresi GA (2020) Mimickers of chronic thromboembolic pulmonary hypertension on imaging tests: a review. Pulm Circ 10:2045894019882620. https://doi.org/10.1177/2045894019882620CrossRefPubMedPubMedCentral

10.

Riedel M, Stanek V, Widimsky J, Prerovsky I (1982) Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest 81(2):151–158CrossRefPubMed

11.

Konstantinides SV, Meyer G, Becattini C et al (2019) 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS): the task force for the diagnosis and management of acute pulmonary embolism of the European society of cardiology (ESC). Eur Respir J 54(3):1901647. https://doi.org/10.1183/13993003.01647-2019CrossRefPubMed

12.

Lasch F, Karch A, Koch A et al (2020) Comparison of MRI and VQ-SPECT as a screening test for patients with suspected CTEPH: CHANGE-MRI study design and rationale. Front Cardiovasc Med 7:51. https://doi.org/10.3389/fcvm.2020.00051CrossRefPubMedPubMedCentral

13.

de Perrot M, Gopalan D, Jenkins D et al (2021) Evaluation and management of patients with chronic thromboembolic pulmonary hypertension – consensus statement from the ISHLT. J Heart Lung Transplant 40(11):1301–1326. https://doi.org/10.1016/j.healun.2021.07.020CrossRefPubMed

14.

Hinrichs JB, Renne J, Hoeper MM, Olsson KM, Wacker FK, Meyer BC (2016) Balloon pulmonary angioplasty: applicability of C‑Arm CT for procedure guidance. Eur Radiol 26(11):4064–4071. https://doi.org/10.1007/s00330-016-4280-zCrossRefPubMed

15.

Humbert MS, Simonneau G, Pittrow D et al (2022) Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 41:716–721. https://doi.org/10.1016/j.healun.2022.02.002CrossRefPubMed

16.

Pengo V, Denas G, Zoppellaro G et al (2018) Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132:1365–1371. https://doi.org/10.1182/blood-2018-04-848333CrossRefPubMed

17.

Nagel C, Prange F, Guth S et al (2012) Exercise training improves exercise capacity and quality of life in patients with inoperable or residual chronic thromboembolic pulmonary hypertension. PLoS One 7:e41603. https://doi.org/10.1371/journal.pone.0041603CrossRefPubMedPubMedCentral

18.

Nagel C, Nasereddin M, Benjamin N et al (2020) Supervised exercise training in patients with chronic thromboembolic pulmonary hypertension as early follow-up treatment after pulmonary endarterectomy: a prospective cohort study. Respiration 99:577–588. https://doi.org/10.1159/000508754CrossRefPubMed

19.

Kim NH, Delcroix M, Jais X et al (2019) Chronic thromboembolic pulmonary hypertension. Eur Respir J 53:1801915. https://doi.org/10.1183/13993003.01915-2018CrossRefPubMedPubMedCentral

20.

Lankeit M, Krieg V, Hobohm L et al (2017) Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant. https://doi.org/10.1016/j.healun.2017.06.011CrossRefPubMed

21.

Delcroix M, Lang I, Pepke-Zaba J et al (2016) Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. Circulation 133:859–871. https://doi.org/10.1161/CIRCULATIONAHA.115.016522CrossRefPubMed

22.

Quadery SR, Swift AJ, Billings CG et al (2018) The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. Eur Respir J 52:1800589. https://doi.org/10.1183/13993003.00589-2018CrossRefPubMedPubMedCentral

23.

Ghofrani HA, D’Armini AM, Grimminger F et al (2013) Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 369:319–329. https://doi.org/10.1056/NEJMoa1209657CrossRefPubMed

24.

Sadushi-Kolici R, Jansa P, Kopec G et al (2019) Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Lancet Respir Med 7:239–248. https://doi.org/10.1016/S2213-2600(18)30367-9CrossRefPubMed

25.

Guth S, D’Armini AM, Delcroix M et al (2021) Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH registry. ERJ Open Res. https://doi.org/10.1183/23120541.00850-2020CrossRefPubMedPubMedCentral

26.

Brenot P, Jais X, Taniguchi Y et al (2019) French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Eur Respir J 53:1802095. https://doi.org/10.1183/13993003.02095-2018CrossRefPubMedPubMedCentral

27.

Kataoka M, Inami T, Hayashida K et al (2012) Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 5:756–762. https://doi.org/10.1161/CIRCINTERVENTIONS.112.971390CrossRefPubMed

28.

Mahmud E, Behnamfar O, Ang L et al (2018) Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Interv Cardiol Clin 7:103–117. https://doi.org/10.1016/j.iccl.2017.09.003CrossRefPubMed

29.

Mizoguchi H, Ogawa A, Munemasa M et al (2012) Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 5:748–755. https://doi.org/10.1161/CIRCINTERVENTIONS.112.971077CrossRefPubMed

30.

Olsson KM, Wiedenroth CB, Kamp JC et al (2017) Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. Eur Respir J 49:1602409. https://doi.org/10.1183/13993003.02409-2016CrossRefPubMed

31.

Inami T, Kataoka M, Yanagisawa R et al (2016) Long-term outcomes after percutaneous transluminal pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Circulation 134:2030–2032. https://doi.org/10.1161/CIRCULATIONAHA.116.024201CrossRefPubMed

32.

Gerges C, Friewald R, Gerges M et al (2021) Efficacy and safety of percutaneous pulmonary artery subtotal occlusion and chronic total occlusion intervention in chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 14(8):e10243. https://doi.org/10.1161/CIRCINTERVENTIONS.120.010243CrossRefPubMed

33.

Ogawa A, Satoh T, Fukuda T et al (2017) Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: results of a multicenter registry. Circ Cardiovasc Qual Outcomes. https://doi.org/10.1161/CIRCOUTCOMES.117.004029CrossRefPubMed

34.

Darocha S, Araszkiewicz A, Kurzyna M et al (2021) Balloon pulmonary angioplasty in technically operable and technically inoperable chronic thromboembolic pulmonary hypertension. J Clin Med. https://doi.org/10.3390/jcm10051038CrossRefPubMedPubMedCentral

35.

Wiedenroth CB, Rolf A, Steinhaus K et al (2022) Riociguat and balloon pulmonary angioplasty improve prognosis in patients with inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant. https://doi.org/10.1016/j.healun.2022.08.011CrossRefPubMed

36.

Jaïs X, Brenot P, Bouvaist H et al (2022) Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. Lancet Respir Med. https://doi.org/10.1016/S2213-2600(22)00214-4CrossRefPubMed

37.

Cannon JE, Su L, Kiely DG et al (2016) Dynamic risk stratification of patient long-term outcome after pulmonary endarterectomy: results from the UK national cohort. Circulation 133:1761–1771. https://doi.org/10.1161/CIRCULATIONAHA.115.019470CrossRefPubMedPubMedCentral

38.

Wiedenroth CB, Liebetrau C, Breithecker A et al (2016) Combined pulmonary endarterectomy and balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 35:591–596. https://doi.org/10.1016/j.healun.2015.10.030CrossRefPubMed

39.

Mayer E, Jenkins D, Lindner J et al (2011) Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg 141:702–710. https://doi.org/10.1016/j.jtcvs.2010.11.024CrossRefPubMed

Titel: Chronic thromboembolic pulmonary hypertension—medical, interventional, and surgical therapy
verfasst von: PD Dr. med. Christoph B. Wiedenroth
Diethard Pruefer
Miriam S. D. Adameit
Eckhard Mayer
Stefan Guth
Publikationsdatum: 25.04.2023
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 4/2023
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-023-05172-8

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

Erratum to: Right ventricular failure in pulmonary hypertension: recent insights from experimental models

Early echocardiographic evaluation of right ventricular load adaptability after sequential combination treatment in pulmonary arterial hypertension

Correlation between decreased plasma miR-29a and vascular endothelial injury induced by hyperlipidemia

Right ventricular failure in pulmonary hypertension: recent insights from experimental models